Pharmaceutical companies must screen and analyze published literature from the clinical development stage through post-marketing as part of their pharmacovigilance obligations. It is critical to detect safety signals as soon as possible to affect appropriate measures and protect patient safety. Medical literature is an important source of information and contributes to the detection of safety signals. The success of published literature surveillance is measured by precision and sensitivity.
Pharmacovigilance & Patient Safety
Clinical trial participants help us speed breakthroughs in modern drug development. Our job is to protect them.
Ask the Experts: What Role Does Patient Safety Play in Our Industry?
When it comes to safety, PRA puts its patients and its people first. Clinical trials are meticulous, with many moving pieces and crucial steps. It’s…
PRA Health Sciences To Report Fourth Quarter 2014 Earnings
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and year end 2014 results after the market closes on Wednesday, February 18,…